Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 1
1998 2
2000 1
2007 1
2008 2
2009 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL. Kievit W, et al. Among authors: de gendt cm. Ann Rheum Dis. 2007 Nov;66(11):1473-8. doi: 10.1136/ard.2007.072447. Epub 2007 Apr 10. Ann Rheum Dis. 2007. PMID: 17426065 Free PMC article. Review.
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL. Blom M, et al. Among authors: de gendt cm. J Rheumatol. 2009 Oct;36(10):2171-7. doi: 10.3899/jrheum.090054. Epub 2009 Sep 1. J Rheumatol. 2009. PMID: 19723902
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC. Kievit W, et al. Among authors: de gendt cm. Ann Rheum Dis. 2008 Sep;67(9):1229-34. doi: 10.1136/ard.2007.083675. Epub 2008 Jan 3. Ann Rheum Dis. 2008. PMID: 18174220
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, van de Laar MA, Van Riel PC. Kievit W, et al. Among authors: de gendt cm. Ann Rheum Dis. 2009 Jun;68(6):844-9. doi: 10.1136/ard.2008.094359. Epub 2008 Jul 14. Ann Rheum Dis. 2009. PMID: 18625616
11 results